Skip to main
OKUR

OKUR Stock Forecast & Price Target

OKUR Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

OnKure Therapeutics Inc. demonstrated improved financial performance in its 2Q25 results, with a recorded net loss of $1.14 per share, which was narrower than the prior estimate of $1.22 per share. The company’s lead drug candidate, OKI-219, has shown promising safety results, being well-tolerated at all dose levels and reporting only Grade 1 treatment-related adverse events without any serious complications. These advancements in clinical outcomes, coupled with a better-than-expected financial report, contribute to a favorable outlook for the company's stock.

Bears say

OnKure Therapeutics Inc. is anticipated to experience a full-year 2025 net loss of $4.56 per share, which reflects a slight improvement over the previous estimate of $4.75 per share. However, several significant risks contribute to a negative outlook, including potential negative clinical results from the lead asset, OKI-219, and possible delays in advancing pipeline candidates to critical regulatory stages. Furthermore, the company faces challenges related to obtaining timely regulatory approvals and intense competition from other therapies, which may result in long-term dilution risks for investors.

OKUR has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OnKure Therapeutics Inc (OKUR) Forecast

Analysts have given OKUR a Strong Buy based on their latest research and market trends.

According to 3 analysts, OKUR has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OnKure Therapeutics Inc (OKUR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.